Your Navigation:PCAR > Abstract
Search pcar
检索项:
检索词:
Abstract
Pharmaceutical Care and Research: 2018; 18(1):63-66
DOI: 10.5428/pcar20180116
Adjustment of drug treatment regimens for critical patients with pneumocystis carinii pneumonia
1. TONG Wei1(1.Department of Pharmacy,Jiangxi Cancer Hospital,Nanchang 330029,China tongwei19860813@126.com)
2. WU Jing2(2.Department of Pharmacy,Hangzhou Obstetrics and Gynecology Hospital,Hangzhou 310008,China )
3. HUANG XingFu3(3.Department of Pharmacy,First People’s Hospital of Qujing,Yunnan Qujing 655000,China )
4. CHEN Hong4(4.Department of Respiration,Ruijin Hospital Affiliated to School of Medicine,Shanghai Jiaotong University,Shanghai 200025,China )
5. FANG Jie5(5.Department of Pharmacy,Ruijin Hospital Affiliated to School of Medicine,Shanghai Jiaotong University,Shanghai 200025,China 13916730218@139.com)
ABSTRACT  Objective: To investigate the drug treatment regimens for critical patients with pneumocytis carinii pneumonia (PCP).Methods: Through direct involvement of clinical pharmacists in the whole drug treatment of 2 immonosuppressed patients,the drug treatment regimens for critical patients with PCP were adjusted,and therapeutic drug efficacy was evaluated and adverse drug reactions were closely monitored in the process.Results: The initial anti-infection treatment of immonosuppressed patients with pulmonary infection should cover PCP.When patients were unable to tolerate high doses of sulfamethodxazole-trimethoprim (SMZ-TMP) or initial treatment with SMZ-TMP was invalid,the combination of SMZ-TMP with caspofungin could be recommended to treat critical PCP.Conclusion: Combination of SMZ-TMP with caspofungin for the treatment of severe PCP had the advantages of faster response,better clinical efficacy,and more importantly,lower incidence of adverse drug reactions.
Welcome to PCAR! You are the number 330 reader of this article!
Please cite this article as:
TONG Wei1,WU Jing2,HUANG XingFu3,CHEN Hong4,FANG Jie5,. Adjustment of drug treatment regimens for critical patients with pneumocystis carinii pneumonia[J]. Pharmaceutical Care and Research / yao xue fu wu yu yan jiu. 2018; 18(1): 63-66.
References:
1. Chinese Medical Association.Clinical diagnosis and treatment guidelines-arch of infectious diseases[M].Beijing:People’s Health Press,2006:138.In Chinese.
2. CAI BoQiang,LI LongYun.PUMC respirology[M].2nd ed.Beijing:China Union Medical University Press,2011:1062.In Chinese.
3. Limper A H,Knox K S,Sarosi G A,et al.An Official American Thoracic Society Statement:treatment of fungal infections in adult pulmonary and critical care patients[J].Am J Respir Crit Care Med,2011,183(1):96-128.
4. SUN PeiPei,TONG ZhaoHui.Efficacy of caspofungin,a 1,3-β-D-glucan synthase inhibitor,on Pneumocystis carinii pneumonia in rats[J].Med Mycol,2014,52:798-803.
5. Cushion M T,Linke M J,Ashbaugh A,et al.Echinocandin treatment of Pneumocystis pneumonia in rodent models depletes cysts leaving trophic burdens that cannot transmit the infection[J].PloS ONE,2010,5(1):e8524.
6. Kim T,Hong H L,Lee Y M,et al.Is caspofungin really an effective treatment for Pneumocystis jirovecii pneumonia in immunocompromised patients without human immunodeficiency virus infection? Experiences at a single center and a literature review[J].Scand J Infect Dis,2013,45(6):484-488.
7. Lobo M L,Esteves F,de Sousa B,et al.Therapeutic potential of caspofungin combined with trimethoprim-sulfamethoxazole for Pneumocystis pneumonia:a pilot study in mice[J].PLoS One,2013,8(8):e70619.
8. YU Bo,WEI XiaoYang,YANG Yu,et al.Clinical study on treatment of Pneumocystis jirovecii pneumonia after renal transplantation by two methods[J].People Mil Surgeon,2010,53(7):491-492.In Chinese.
9. TU GuoWei,JU MinJie,XU Ming,et al.Combination of caspofungin and low-dose trimethoprim/sulfamethoxazole for the treatment of severe Pneumocystis jirovecii pneumonia in renal transplant recipients[J].Nephrol,2013,18:736-742.
10. Sanford J P.Pyreticosis: Sanford guide to antimicrobial therapy[M].Translated by FAN HongWei,et al.44th ed.Beijing:China Union Medical University Press,2014:44.In Chinese.
11. LUN XinQiang.An analysis of adverse reactions induced by compound sulfamethoxazole tablets in 267 cases[J].Chin J Phanmcoepidemiol,2004,13(3):139-140,153.In Chinese with English abstract.
《药学服务与研究》杂志社 All Rights Reserved 网站备案号:鲁B2-20061008
·地址:上海市杨浦区长海路168号18号楼东三楼 邮政编码:200433
·联系电话(传真):86-21-65519829, 021-31162330
·电子邮件:PharmCR@vip.163.com
·技术支持:中国康网
管理员入口